We use cookies to give you a better Web experience. By visiting our website you agree to our use of cookies. Read about cookies
OK
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

Mandate Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

April 01, 2020

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Clarification of the interpretation of ”nearest suitable railway station”

 Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020

DAC 6 – EU Directive concerning reportable cross‑border tax arrangements

 DAC 6 is a EU Directive which entails that advisers are subject to a duty to notify the relevant tax authorities concerning their client’s cross‑border arrangements. The purpose of the information disclosure obligation is to combat tax evasion, tax fraud and tax avoidance.
June 04, 2020

The importance of continuous focus on compliance procedures in disrupting times

 A large number of corporations will most certainly be severely impacted by the effects of the Covid-19 pandemic. The new challenges will impact companies’ compliance risks, which are likely to be different and, to a certain extent, increased. It is crucial that - also in disrupting times - internal compliance procedures are maintained and that new risks are identified and mitigated.
May 28, 2020